Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qianlietongshuang Capsule is a traditional Chinese medicine (TCM) developed by Chengdu Hekang Pharmaceutical Co., Ltd. for the treatment of benign prostatic hyperplasia (BPH). It is specifically indicated for patients presenting with blood stasis obstruction syndrome, a TCM diagnostic category often associated with urinary symptoms and prostate enlargement. The formulation consists of multiple botanical extracts intended to alleviate urinary obstruction and improve flow. It has been evaluated in randomized, double-blind Phase 2 clinical trials in China, where its safety and efficacy were compared against other TCM treatments such as Zeguilongshuang Capsule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qianlietongshuang Capsule.